Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves first pharmacologic treatment of ROP for preterm infants
➤ FDA accepts NDA for dilation reversal drop
➤ Phase 2b results for anti-VEGF agent for wet AMD
➤ Interim results for Phase 1 study evaluating hydrogel implant for retinal diseases
➤ Data from ongoing Phase 1/2 clinical trial of gene therapy for Leber congenital amaurosis
➤ ASCRS news and events
➤ FDA accepts NDA for dry eye treatment
➤ Phase 2 study moves forward for investigational ocular autoimmune therapy
➤ Fast-track designation granted for investigational retinitis pigmentosa treatment
➤ First-in-human feasibility study data from drug-eluting IOL platform
➤ Study identifies the ‘best approach’ for anti-VEGF therapy for diabetic retinopathy
➤ ASCRS news and events
➤ FDA approves treatment for subfoveal choroidal neovascularization due to AMD
➤ IND for inherited RPE clinical trial receives FDA clearance
➤ Phase 3 clinical trial to evaluate cooling device for anesthesia prior to injections
➤ Study calls ‘long-believed theory about diabetic cataracts into question’
➤ ASCRS news and events
➤ Alert: eye infections linked to artificial tear
➤ Phase 2 data from research targeting Sjogren’s treatment
➤ First patient dosed in Phase 1 study for epithelial defect treatment
➤ Study compares DMEK tissue preparation techniques
➤ Topline results from oral diabetic retinopathy treatment trial
➤ ASCRS news and events
➤ Bausch + Lomb acquires AcuFocus
➤ Study: novel drug delivery system sees less inflammation with preserved drops
➤ Meibomian gland atrophy common among cataract patients, study finds
➤ mRNA technology investigated for gene therapy to treat blindness
➤ Studies find new bionic vision system offers improved outcomes
➤ ASCRS news and events
➤ Clinical trial for new cataract surgery technology
➤ Topline results from Phase 2 trial investigating treatment for persistent corneal epithelial defect
➤ Update on sustained-release glaucoma implant and Glaukos cornea programs
➤ First patient enrolled in Phase 3 trial for presbyopia drop
➤ ASCRS news and events
➤ FDA approves NDA for IOP-lowering drug
➤ NDA submitted for presbyopia drop
➤ IND accepted for investigational treatment of persistent corneal epithelial defect
➤ Topline results from Phase 2 study of novel sedation drug for cataract surgery
➤ First patient enrolled in Phase 3 trial for investigational TED therapy
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ FDA accepts NDA for pupil dilation spray
➤ NDA for new glaucoma drug accepted
➤ PMA application submitted to FDA for new IOL
➤ Data report: 12-month efficacy seen from single mechanical MGD treatment
➤ Acquisition of company developing drugs for rare ophthalmic diseases
➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis
➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis
➤ FDA approves IND for research to move forward on RP gene therapy
➤ Phase 2 study to treat geographic atrophy begins
➤ Study: Weaning patients off of AMD treatments compared
➤ Possible geographic atrophy treatment explored
➤ ASCRS news and events
➤ NDA submitted for new, topical dry eye disease treatment
➤ IND submitted for persistent corneal epithelial defect treatment
➤ IND filed for dry eye disease treatment
➤ Study: Investigational topical drop reduces inflammation in anterior uveitis cases
➤ Alcon completes acquisition of Aerie
➤ ASCRS news and events